Pediatric inflammatory bowel disease (IBD) is commonly treated with infliximab in a hospital setting or clinic where infusions are safely and effectively administered. In recent years, utilization of home infusions (HI) has increased due to reduced costs (insurance mandates) and patient factors (e.g., travel time savings, convenience). While 1 study of adult IBD patients found a higher likelihood for adverse outcomes among HI compared to those hospital-infused, the safety and efficacy of HI in children is understudied.